Abstract
Metastatic colorectal cancer (MCRC) management has improved significantly in the past decade. Several medications have been approved since the late 1990s, resulting in significant improvements in overall survival. Therapy continues to evolve with the discovery of various genetic differences which predict response to individual targeted agents.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 33-36 |
| Number of pages | 4 |
| Journal | Journal of Managed Care Medicine |
| Volume | 16 |
| Issue number | 3 |
| State | Published - Sep 16 2013 |
Keywords
- Biologics target key regulators of tumor cell growth, survival, metastasis, and angiogenesis
- I mproved health outcomes can be achieved by using genetic mutation testing to avoid ineffective chemotherapy and potential side effects and expedite access to the most effective treatment
- Metastatic colorectal cancer is still considered not curable
- The presence of genetic mutations, including KRAS and BRAF mutations, can be used to guide biologic agent selection
- Therapies approved in recent years have significantly improved median survival
ASJC Scopus subject areas
- Health Policy